Efficacy and Safety Study of Creon IR in Subjects With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Exocrine Pancreatic Insufficiency in Subjects With Cystic Fibrosis
Interventions
DRUG

Creon IR

DRUG

Creon® (DR/GR)

Trial Locations (17)

2045

Tüdőgyógyintézet Törökbálint, Törökbálint

4031

Kenézy Gyula Kórház, Debrecen

7400

Kaposi Mór Oktató Kórház, Kaposvár

8400

Magyar Imre Kórház, Ajka

28006

Hospital Universitario de La Princesa, Madrid

28046

Hospital Universitario La Paz, Madrid

29009

Hospital Carlos Haya, Hospital Civil, Secretaria de Endocrinologia, Málaga

41013

Hospital Universitario Virgen del Rocío, Hospital de la Mujer, Seville

46026

Hospital La Fé Valencia, Valencia

61300

Dětská nemocnice FN Brno, Centrum pro cystickou fibrozu, Brno

62500

Klinika nemocí plicních a TBC, Brno

58-540

Centrum Medyczne Karpacz S.A., Karpacz

93-513

Wojewódzki Szpital Specjalistyczny Im M Kopernika W Łodzi, Lodz

34-700

"Janusz Stankiewicz Sanatorium Cassia-Villa Medica", Rabka-Zdrój

35-612

Podkarpacki Ośrodek Pulmonologii i Alergologii, Rzeszów

01-195

ENEL-MED Szpital Centrum, Warsaw

08035

Hospital Vall d ´Hebron, Barcelona

Sponsors
All Listed Sponsors
collaborator

AbbVie

INDUSTRY

collaborator

LKF Laboratorium für Klinische Forschung GmbH

UNKNOWN

collaborator

Analytical Biochemical Laboratory

UNKNOWN

collaborator

Parexel

INDUSTRY

collaborator

Datamap

INDUSTRY

collaborator

Linical Co., Ltd.

INDUSTRY

lead

Abbott

INDUSTRY